Approval of esketamine for treatment-resistant depression

Affiliations

¹ Neuroscience Clinical Development, Janssen Research & Development, San Diego, CA, USA.
² Janssen Scientific Affairs, Titusville, NJ 08560, USA. Electronic address: edaly2@its.jnj.com.
³ Neuroscience Global Medical Affairs, Janssen Research & Development, Titusville, NJ, USA.
⁴ Neuroscience Clinical Development, Janssen Research & Development, Titusville, NJ, USA.
⁵ Neuroscience Clinical Development, Janssen Research & Development, Beerse, Belgium.

Comment

Jaskaran B Singh et al. Lancet Psychiatry. 2020 Mar.

. 2020 Mar;7(3):232-235.

doi: 10.1016/S2215-0366(19)30533-4.

¹ Neuroscience Clinical Development, Janssen Research & Development, San Diego, CA, USA.
² Janssen Scientific Affairs, Titusville, NJ 08560, USA. Electronic address: edaly2@its.jnj.com.
³ Neuroscience Global Medical Affairs, Janssen Research & Development, Titusville, NJ, USA.
⁴ Neuroscience Clinical Development, Janssen Research & Development, Titusville, NJ, USA.
⁵ Neuroscience Clinical Development, Janssen Research & Development, Beerse, Belgium.

No abstract available

Comment in

Approval of esketamine for treatment-resistant depression - Authors' reply.
Naudet F, Cristea IA. Naudet F, et al. Lancet Psychiatry. 2020 Mar;7(3):235-236. doi: 10.1016/S2215-0366(20)30040-7. Lancet Psychiatry. 2020. PMID: 32087802 No abstract available.

US Food and Drug Administration approval of esketamine and brexanolone.
Cristea IA, Naudet F. Cristea IA, et al. Lancet Psychiatry. 2019 Dec;6(12):975-977. doi: 10.1016/S2215-0366(19)30292-5. Epub 2019 Nov 1. Lancet Psychiatry. 2019. PMID: 31680013 No abstract available.
Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval.
Turner EH. Turner EH. Lancet Psychiatry. 2019 Dec;6(12):977-979. doi: 10.1016/S2215-0366(19)30394-3. Epub 2019 Nov 1. Lancet Psychiatry. 2019. PMID: 31680014 No abstract available.